Results 71 to 80 of about 7,495 (248)

Alkaloids from Fissistigma latifolium (Dunal) Merr.

Molecules, 2010
A phytochemical study of the bark of Fissistigma latifolium (Annonaceae) yielded a new aporphine alkaloid, (-)-N-methylguattescidine (1), and eight known alkaloids: liriodenine (2), oxoxylopine (3), (-)-asimilobine (4), dimethyltryptamine (5 ...
Asmah Alias, Hazrina Hazni, Faridahanim Mohd Jaafar, Khalijah Awang, Nor Hadiani Ismail   +4 more
doaj   +1 more source

Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice [PDF]

, 2017
New psychoactive substances (NPS) are a new breed of synthetically produced substances designed to mimic the effects of traditional illegal drugs. Synthetic cannabinoids and synthetic cathinones are the two most common groups, which try to mimic the ...
Barneo-Muñoz, Manuela, Fabregat-Safont, David, Hernandez, Felix, Ibáñez, Maria, Martínez García, Fernando, Sancho, Juan V   +5 more
core   +2 more sources

Enlightening the “Spirit Molecule”: Photomodulation of the 5‐HT2A Receptor by a Light‐Controllable N,N‐Dimethyltryptamine Derivative

Angewandte Chemie, 2022
Classical psychedelics are a group of hallucinogens which trigger non‐ordinary states of consciousness through activation of the 5‐HT2A receptor (5‐HT2AR) in the brain. However, the exact mechanism of how 5‐HT2AR agonism alters perception remains elusive.
Hubert Gerwe, Feng He, E. Pottie, C. Stove, Michael Decker   +4 more
semanticscholar   +1 more source

Quantitative Analysis of Substituted -Dimethyl-tryptamines in the Presence of Natural Type XII Alkaloids

Natural Product Communications, 2012
This paper reports the qualitative and quantitative analysis (QA) of mixtures of hallucinogens, N,N -dimethyltryptamine (DMT) ( 1 ), 5-methoxy- ( 1a ) and 5-hydroxy- N,N -dimethyltryptamine ( 1b ) in the presence of β-carbolines (indole alkaloids of type
Bojidarka Ivanova, Michael Spiteller
doaj   +1 more source

Novel Psychoactive Substances: : the pharmacology of stimulants and hallucinogens [PDF]

, 2016
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Clinical Pharmacology, on March 2016, available online at doi: : http://www.tandfonline.com/doi/full/10.1586/17512433.2016.1167597.There are increasing levels ...
Corkery JM, Daly M, Dargan PI, Fabrizio Schifano, Farrè M, G. Duccio Papanti, John M. Corkery, Laura Orsolini, Shulgin AT, Shulgin AT, Soussan C, Ujváry I   +11 more
core   +3 more sources

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors

Cellular and Molecular Life Sciences
The potent hallucinogen N,N-dimethyltryptamine (DMT) has garnered significant interest in recent years due to its profound effects on consciousness and its therapeutic psychopotential.
K. Egger, H. Aicher, Paul Cumming, M. Scheidegger   +3 more
semanticscholar   +1 more source

Novel psychoactive substances of interest for psychiatry [PDF]

, 2015
Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a ...
Corkery, John, Orsolini, Laura, Papanti, Duccio, Schifano, Fabrizio   +3 more
core   +1 more source

Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence

Frontiers in Psychiatry, 2022
Background The psychedelic 5-MeO-DMT has shown clinical potential due to its short duration and ability to induce mystical experiences. However, a phenomenon known as “reactivations” (similar to “flashbacks”) is a poorly understood and frequently ...
A. Ortiz Bernal, C. Raison, R. Lancelotta, A. K. Davis   +3 more
semanticscholar   +1 more source

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović, Kent W. Nilsson, Robert Fredriksson, Helgi B. Schiöth, Thiago C. Moulin   +4 more
wiley   +1 more source